BMS-986490 (Not yet branded)
Other Medications
Description
BMS-986490 is an anti-cancer compound developed by Bristol Myers Squibb that is being evaluated in advanced solid tumors including colorectal cancer. This agent is designed to work either as monotherapy or in combination with bevacizumab, an anti-angiogenic therapy. Based on its development pattern and combination strategy, it appears to target specific molecular pathways involved in tumor growth and progression.
Mechanism of Action
The precise molecular mechanism of BMS-986490 has not been fully disclosed in public databases, though its pairing with bevacizumab suggests it may complement anti-angiogenic approaches. The compound likely targets specific proteins or signaling pathways that contribute to tumor cell survival, proliferation, or resistance mechanisms in solid tumors.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Administration | IV |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.